Dose induction PEG-Intron [peginterferon alfa-2b] in combination with Rebetol [ribavirin] enhance the sustained response rates in patients with chronic hepatitis C.
Phase of Trial: Phase IV
Latest Information Update: 13 Feb 2012
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Feb 2012 Actual patient number changed from 604 to 610 as reported by ClinicalTrials.gov.
- 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History